1-15 of 15
Hyacinthe Johnson-Ansah
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Treatment Free Survival (TFS) in Patients (pts) with Chronic Myeloid Leukemia (CML) Carrying Atypical BCR-ABL1 Fusion Transcripts: The French CML Group (Fi-LMC) Experience

Hyacinthe Johnson-Ansah, Aude Charbonnier, Delphine Rea, Gabriel Etienne, Lydia Roy, Laurence Legros, Agnes Guerci Bresler, Anne Bouvier, Emilie Cayssials, Valerie Coiteux, Philippe Rousselot, Stephanie Dulucq, Sandrine Hayette, Francois-Xavier Mahon, Franck E. Nicolini
Journal: Blood
Blood (2021) 138 (Supplement 1): 3604.
https://doi.org/10.1182/blood-2021-147537
Published: 2021
Journal Articles

Treatment-Free Remissions in Newly Diagnosed CP CML Patients Treated with the Combination of Nilotinib + Pegylated Interferon Alpha 2a Versus Nilotinib Alone in the National Phase III Petals Trial

Franck E. Nicolini, Gabriel Etienne, Francoise Huguet, Agnès Guerci-Bresler, Aude Charbonnier, Martine Escoffre-Barbe, Viviane Dubruille, Hyacinthe Johnson-Ansah, Laurence Legros, Valerie Coiteux, Pascale Cony-Makhoul, Pascal Lenain, Lydia Roy, Philippe Rousselot, Denis Guyotat, Jean-Christophe Ianotto, Corentin Orvain, Eric Deconinck, Denis Caillot, Pascal Turlure, Stephane Courby, Philippe Quittet, Eric Hermet, Shanti Amé, Simona Lapusan, Stephane Morisset, Francois-Xavier Mahon, Delphine Rea, Stephanie Dulucq
Journal: Blood
Blood (2021) 138 (Supplement 1): 2553.
https://doi.org/10.1182/blood-2021-146412
Published: 2021
Journal Articles

The Combination of Nilotinib + Pegylated IFN Alpha 2a Provides Somewhat Higher Cumulative Incidence Rates of MR4.5 at M36 Versus Nilotinib Alone in Newly Diagnosed CP CML Patients. Updated Results of the Petals Phase III National Study.

Franck E Nicolini, MD PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnès Guerci-Bresler, MD PhD, Aude Charbonnier, MD PhD, Martine Escoffre-Barbe, MD, Viviane Dubruille, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MD PhD, Valerie Coiteux, MD, Pascale Cony-Makhoul, MD, Pascal Lenain, MD, Lydia Roy, MD, Philippe Rousselot, MD PhD, Denis Guyotat, MD PhD, Jean-Christophe Ianotto, MD PhD, Martine Gardembas, MD, Eric Deconinck, MD PhD, Fabrice Larosa, MD, Denis Caillot, MD, Pascal Turlure, MD, Stephane Courby, MD, Philippe Quittet, MD, Eric Hermet, MD, Shanti Ame, MD, Simona Lapusan, MD, Alexandre Deloire, CRA, Stephane Morisset, BioStat, Madeleine Etienne, CRA, Delphine Rea, MD, Stephanie Dulucq, PharmD, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 494.
https://doi.org/10.1182/blood-2019-123674
Published: 2019
Journal Articles

First-Line Second Generation Tyrosine Kinase Inhibitors in Newly Diagnosed Accelerated Phase Chronic Myeloid Leukemia Patients.

Marie Balsat, MD, Vincent Alcazer, MD, Gabriel Etienne, MD PhD, Gaelle Fossard, MD, Francoise Huguet, MD, Marc G. Berger, MD PhD, Emilie Cayssials, MD, Aude Charbonnier, MD, Martine Escoffre-Barbe, MD, Hyacinthe Johnson-Ansah, MD, Viviane Dubruille, MD, Laurence Legros, MD PhD, Lydia Roy, MD, Alain Jacques Delmer, MD, Jean-Christophe Ianotto, MD PhD, Martine Gardembas, MD, Fabrice Larosa, Stephane Courby, MD, Shanti Ame, MD, Stephane Morisset, Stat, Francois-Xavier Mahon, MD PhD, Delphine Rea, MD, Franck Emmanuel Nicolini, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 48.
https://doi.org/10.1182/blood-2018-99-113058
Published: 2018
Journal Articles

Nilotinib Versus Nilotinib Combined to Pegylated-Interferon Alfa 2a in First-Line Chronic Phase Chronic Myelogenous Leukemia Patients. Interim Analysis of a Phase III Trial

Franck Emmanuel Nicolini, MD PhD, Gabriel Etienne, MD PhD, Francoise Huguet, MD, Agnes Guerci-Bresler, Aude Charbonnier, MD, Martine Escoffre-Barbe, MD, Viviane Dubruille, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MDPhD, Valerie Coiteux, MD, Pascale Cony-Makhoul, MD PhD, Pascal Lenain, MD, Lydia Roy, MD, Philippe Rousselot, Denis Guyotat, Jean-Christophe Ianotto, MD, Martine Gardembas, MD, Fabrice Larosa, MD, Denis Caillot, MD, Pascal Turlure, MD, Stephane Courby, MD, Philippe Quittet, MD, Eric Hermet, MD, Shanti Ame, MD, Simona Lapusan, MD, Verane Schwiertz, PharmD, Stephane Morisset, Stat, Madeleine Etienne, CRA, Delphine Rea, MD PhD, Stephanie Dulucq, PhD, Francois-Xavier Mahon, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 899.
https://doi.org/10.1182/blood.V130.Suppl_1.899.899
Published: 2017
Journal Articles

Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Clinical Trials & Observations
Delphine Rea, Franck E. Nicolini, Michel Tulliez, François Guilhot, Joelle Guilhot, Agnès Guerci-Bresler, Martine Gardembas, Valérie Coiteux, Gaelle Guillerm, Laurence Legros, Gabriel Etienne, Jean-Michel Pignon, Bruno Villemagne, Martine Escoffre-Barbe, Jean-Christophe Ianotto, Aude Charbonnier, Hyacinthe Johnson-Ansah, Marie-Pierre Noel, Philippe Rousselot, François-Xavier Mahon, for the France Intergroupe des Leucémies Myéloïdes Chroniques
Journal: Blood
Blood (2017) 129 (7): 846–854.
https://doi.org/10.1182/blood-2016-09-742205
Published: 2017
Journal Articles

Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study

Philippe Rousselot, MD PhD, Hyacinthe Johnson-Ansah, MD, Françoise Huguet, MD, Laurence Legros, MD, Martine Escoffre-Barbe, Martine Gardembas, MD, Pascale Cony-Makhoul, MD, Valérie Coiteux, MD, Laurent Sutton, MD, Wajed Abarah, MD, Camille Pouaty, MD, Jean Michel Pignon, MD, Bachra Choufi, MD, Sorin Visanica, MD, Bénédicte Deau, MD, Stephane Bouchet, MDPhD, Francois Guilhot, MD, Francois-Xavier Mahon, MD PhD Professor, Laure Morisset, Jean-Michel Cayuela, Benjamin Maneglier, MD
Journal: Blood
Blood (2015) 126 (23): 133.
https://doi.org/10.1182/blood.V126.23.133.133
Published: 2015
Journal Articles

Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)

Lydia ROY, MD, Jean-Claude Chomel, PharmD PhD, Joelle Guilhot, PhD, Agnes Guerci-Bresler, MD, Martine Escoffre-Barbe, Stéphane Giraudier, MD PhD, Aude Charbonnier, Viviane Dubruille, MD, Françoise Huguet, Hyacinthe Johnson-Ansah, MD, Pascal Lenain, MD, Shanti Amé, MD, Gabriel Etienne, MD PhD, Franck E. Nicolini, Delphine Rea, MD PhD, Pascale Cony-Makhoul, MD, Stephane Courby, MD, Jean-Christophe Ianotto, MD, Laurence Legros, MD, Martine Delain, MD, Valérie Coiteux, MD, Eric Hermet, MD, Martine Gardembas, MD, Mathieu Molimard, MD PhD, Jean-Michel Cayuela, Marie Thibaud, CRA, Sophie Duranton, PharmD, Francois-Xavier Mahon, MD PhD, Philippe Rousselot, MD PhD Professor, Francois Guilhot, MD
Journal: Blood
Blood (2015) 126 (23): 134.
https://doi.org/10.1182/blood.V126.23.134.134
Published: 2015
Journal Articles

Prospective Analysis of the Quality of Life of Chronic Phase CML Patients on Second Generation Tyrosine Kinase Inhibitors after Imatinib Failure. an Observational Study

Franck E. Nicolini, MD PhD, Nicolas Vantard, Pharm.D, Stephane Giraudier, MD PhD, Mael Heiblig, MD, Hyacinthe Johnson-Ansah, MD, Lydia Roy, MD, Claude-Eric Bulabois, MD, Denis Caillot, MD, Martine Escoffre-Barbe, MD, Eric Jourdan, MD PhD, Pascale Cony-Makhoul, MD, Agnes Guerci-Bresler, MD PhD, Laurence Legros, MD PhD, Laurent Sutton, MD, Martine Gardembas, MD, Emmanuel Gyan, MD PhD, Annelore Le Maux, Stat., Carine Guinard-Azadian, MD, Hesham Mohamed, MD, Mohamad Sobh, Pharm.M., Helene Labussiere-Wallet, MD, Gabriel Etienne, MD PhD
Journal: Blood
Blood (2014) 124 (21): 1321.
https://doi.org/10.1182/blood.V124.21.1321.1321
Published: 2014
Journal Articles

A T315I Gate Keeper Mutation Responding To Pegylated Interferon Alfa-2a (Peg-IFN) Monotherapy With Major Molecular Response (MMR4) At 12 Months In An Imatinib-Resistant Chronic Myeloid Leukemia (CML) Patient

Hyacinthe Johnson-Ansah, MD, Dina Naguib, MD, Hervé Mittre, MD, Seyefeddine Kadi, MD, Xavier Troussard, MD
Journal: Blood
Blood (2013) 122 (21): 5179.
https://doi.org/10.1182/blood.V122.21.5179.5179
Published: 2013
Journal Articles

Prediction Of Second Generation Tyrosine Kinase Inhibitors Response After Imatinib Failure: The Value Of The Hammersmith Prediction Score

Franck E. Nicolini, MD, PhD, Philippe Rousselot, MD, PhD, Stephane Giraudier, MD, PhD, Gabriel Etienne, MD, PHD, Hyacinthe Johnson-Ansah, MD, Lydia Roy, MD, Pascale Cony-Makhoul, MD, Yann Guillermin, MD, Mohamad Sobh, Pharm.M., Pierre Marie, CRA, Driss Kamar, Biostat, Hesham Mohamed, MD, Denis Caillot, MD, Delphine Rea, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 383.
https://doi.org/10.1182/blood.V122.21.383.383
Published: 2013
Journal Articles

Relationship Between Molecular Responses and Disease Progression in Patients (Pts) Treated First Line with Imatinib (Im) Based Regimens: Impact of Treatment Arm within the French Spirit Trial From the French CML Group (FI LMC)

Philippe Rousselot, MD, PhD, Joelle Guilhot, PhD, Claude Preudhomme, Francois-Xavier Mahon, MD, PhD, Delphine Rea, MD, PhD, Franck E. Nicolini, MD, PhD, Francoise Rigal-Huget, MD, Hyacinthe Johnson-Ansah, MD, Anne Vekhoff, MD, Agnès Guerci-Bresler, MD, Eric Jourdan, MD, Laurence Legros, MD, PhD, Francois Guilhot
Journal: Blood
Blood (2012) 120 (21): 168.
https://doi.org/10.1182/blood.V120.21.168.168
Published: 2012
Journal Articles

Pegylated Interferon a2a (PegIFN) At the Dose of 45μg Per Week in Combination with Imatinib 400mg Is the Recommended Initial Dose for Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP): Results From the French SPIRIT Trial of the French CML Group (FI LMC)

Hyacinthe Johnson-Ansah, MD, Joelle Guilhot, Philippe Rousselot, MD, PhD, Rea Delphine, MD, PhD, Francoise Rigal-Huguet, MD, Franck E. Nicolini, MD, PhD, Anne Vekhoff, MD, Agnès Guerci-Bresler, MD, PhD, Michele Schoenwald, MD, Eric Jourdan, Laurence Legros, Valérie Coiteux, MD, Francois-Xavier Mahon, MD, PhD, Claude Preudhomme, Francois Guilhot
Journal: Blood
Blood (2011) 118 (21): 456.
https://doi.org/10.1182/blood.V118.21.456.456
Published: 2011
Journal Articles

Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Franck Emmanuel Nicolini, MD, PhD, Gabriel Etienne, MD, Dominique Bordessoule, Denis Caillot, MD, Coralie Belanger, Jean-Michel Cayuela, MD, Aude Charbonnier, Valerie Coiteux, MD, Agnès Guerci-Bresler, Viviane Dubruille, Thierry Lamy, MD, PhD, Francoise Huguet, Philippe Rousselot, MD, PhD, Michel Tulliez, Jean-Yves Cahn, Martine Gardembas-Pain, Laurence Legros, MD, Frederic Maloisel, Delphine Rea, MD, PhD, Hyacinthe Johnson-Ansah, MD, Pascal Lenain, Alain Delmer, MD, PhD, Marc Berger, MD, Tomasz Szczudlo, MD, Jim Wang, PhD, Mei Sheng Duh, MPH, ScD, Francois Guilhot, MD
Journal: Blood
Blood (2009) 114 (22): 3293.
https://doi.org/10.1182/blood.V114.22.3293.3293
Published: 2009
Journal Articles

Front-Line Imatinib Mesylate (IM) in Patients with Newly Diagnosed Accelerated Phase (AP)-Chronic Myeloid Leukemia (CML), a Study From the FILMC Group (France Intergroupe Leucemie Myeloide Chronique).

Delphine Rea, MD, PhD, Gabriel Etienne, MD, Franck Emmanuel Nicolini, MD, PhD, Pascale Cony-Makhoul, MD, Hyacinthe Johnson-Ansah, MD, Laurence Legros, MD, Francoise Huguet, MD, Michel Tulliez, MD, Martine Gardembas, MD, Krimo Bouabdallah, MD, Philippe Rousselot, MD, PhD, Jean-Michel Cayuela, PhD, Herve Dombret, MD, PhD, François-Xavier Mahon, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 3288.
https://doi.org/10.1182/blood.V114.22.3288.3288
Published: 2009